PharmAla Launches MDMA Clinical Trial Tool for Researchers
August 22, 2024 09:07 ET
|
PharmAla Biotech
PharmAla announces the launching of a new tool for clinical researchers, and the appointment of a new CFO effective Oct. 1
MAPS Statement on FDA Complete Response Letter for MDMA-Assisted Therapy for PTSD New Drug Application
August 09, 2024 21:33 ET
|
Multidisciplinary Association for Psychedelic Studies (MAPS)
MAPS remains confident in its goal of making access to MDMA-assisted therapy for PTSD safe and legal SAN JOSE, Calif., Aug. 09, 2024 (GLOBE NEWSWIRE) -- The Multidisciplinary Association for...
PsyCan Comments on FDA Decision Re: Lykos MDMA-Assisted Therapy Application
August 09, 2024 18:28 ET
|
Psychedelics Canada
Psycan comments on USFDA's recent decision to request a third phase 3 trial prior to approval of
PharmAla Comments on USFDA Decision regarding MDMA-Assisted Therapy and Announces Patent Granting for ALA-002
August 09, 2024 18:18 ET
|
PharmAla Biotech
PharmAla expresses disappointment in USFDA's decision to request a third Phase 3 for MDMA and announces the patent granting for a safer MDMA analog variant
PharmAla Provides Comprehensive Investor Update Following Release of Q3 Financial Statement
July 30, 2024 08:55 ET
|
PharmAla Biotech
PharmAla releases a comprehensive investor update following its Q3 financial release, including highlights such as a 10x revenue increase and patent update
Optimi Health Secures Import Permit from Mind Medicine Australia for MDMA and Psilocybin Capsules
May 29, 2024 08:00 ET
|
Optimi Health Corp.
Optimi Health preparing to export 160 doses of MDMA and psilocybin under Australia’s Authorized Prescriber Scheme.
Optimi Health, ATMA Sign Letter of Intent To Advance Phase II Clinical Trial Group and Individual Administration Protocol For Major Depressive Disorder
May 22, 2024 08:30 ET
|
Optimi Health Corp.
Optimi Health, ATMA Sign Letter of Intent To Advance Phase II Clinical Trial Group and Individual Administration Protocol For Major Depressive Disorder
Optimi Health Provides Corporate Update
May 10, 2024 08:50 ET
|
Optimi Health Corp.
Optimi Health provides corporate update.
Optimi Health Receives Export Permit from Health Canada to Ship MDMA To Tel Aviv University's Institute for Psychedelic Research
May 09, 2024 08:00 ET
|
Optimi Health Corp.
Export Permit granted: Optimi's Shipment of MDMA active pharmaceutical ingredient (API) to Israel marks the Company’s first international export
PharmAla Launches Prescriber’s Portal for Medical Professionals Focused on MDMA Therapy
May 03, 2024 11:00 ET
|
PharmAla Biotech
PharmAla launches new educational resource for prescribers of MDMA through the Special Access Program